Study on the effectiveness of COVID-19 measures in the Netherlands The measures implemented in the Netherlands during the COVID-19 crisis were effective against the spread of the SARS-CoV-2 virus. This is the outcome of a study conducted by RIVM.
National cervical cancer screening campaign under way Today sees the kick-off of the national campaign: Let’s talk about cervical cancer – have you #done the smear test or self-test yet? This marks the first time that RIVM, Bevolkingsonderzoek Nederland and the KWF Dutch Cancer Society are launching a joint campaign to call attention to cervical cancer screening.
Strong interest among schools in incentive to promote healthy and sustainable eating Schools are highly interested in the promotional incentive of a programme teaching young children to eat healthy from a young age. The incentive is called ‘Let’s go outside for tasty food!’ or Lekker naar buiten! in Dutch. 2,273 schools applied for the funding over a three year period.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
Self-sampling device to be sent automatically, making it easier to take part in cervical cancer screening From the first week of July, every woman turning 30 will receive a self-sampling device with their invitation for cervical cancer screening. Participants can use this device to collect their own vaginal material.
Number of participants in Combined Lifestyle Intervention tops 73,000 By the end of 2022, the number of participants in the Combined Lifestyle Intervention (CLI) had grown to over 73,000. This is according to a semi-annual report by RIVM. The figure represents a 51% increase since the end of May 2022. The number of participants was around 48,000 at that time.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Key persons should be involved in policy for pandemics RIVM advises government authorities to involve ‘key persons’ in formulating policy for current and future pandemics. Results from RIVM research show that these individuals played a key role in ensuring an ongoing focus on social well-being and mental health during the COVID-19 pandemic, despite the limitations.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.